Cytokinetics to Participate in Upcoming Investor Conferences
September 07, 2023 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor...
Cytokinetics Announces Start of ACACIA-HCM, a Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
September 06, 2023 07:30 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that ACACIA-HCM (Assessment Comparing Aficamten to Placebo on Cardiac...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 01, 2023 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on August 31, 2023 it granted stock options to purchase an aggregate of...
Cytokinetics Reports Second Quarter 2023 Financial Results
August 03, 2023 16:00 ET
|
Cytokinetics, Incorporated
Completed Enrollment in SEQUOIA-HCM, Pivotal Phase 3 Trial of Aficamten in Obstructive HCM; On Track for Topline Results by the End of the Year Initiated Enrollment in MAPLE-HCM, a Phase 3 Clinical...
Cytokinetics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
August 01, 2023 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on July 31, 2023 it granted stock options to purchase an aggregate of...
Cytokinetics to Announce Second Quarter Results on August 3, 2023
July 27, 2023 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report second quarter results on August 3, 2023 at...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 05, 2023 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., July 05, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on June 30, 2023 it granted stock options to purchase an aggregate of...
Cytokinetics Announces Start of MAPLE-HCM, a Phase 3 Clinical Trial of Aficamten Compared to Metoprolol in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
June 20, 2023 07:30 ET
|
Cytokinetics, Incorporated
First Phase 3 Trial Evaluating Monotherapy with a Cardiac Myosin Inhibitor Compared to Monotherapy with a Beta Blocker in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy SOUTH SAN...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
June 02, 2023 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., June 02, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on May 31, 2023 it granted stock options to purchase an aggregate of...
Cytokinetics to Participate in Upcoming Investor Conferences
June 01, 2023 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor...